Reactive Extraction of Lactic Acid, Formic Acid and Acetic Acid from Aqueous Solutions with Tri-N-Octylamine/1-Octanol/N-Undecane
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Modelling and Numerical Simulation of Phase Separation in Polymer Modified Bitumen by Phase- Field Method
http://www.diva-portal.org Postprint This is the accepted version of a paper published in Materials & design. This paper has been peer- reviewed but does not include the final publisher proof-corrections or journal pagination. Citation for the original published paper (version of record): Zhu, J., Lu, X., Balieu, R., Kringos, N. (2016) Modelling and numerical simulation of phase separation in polymer modified bitumen by phase- field method. Materials & design, 107: 322-332 http://dx.doi.org/10.1016/j.matdes.2016.06.041 Access to the published version may require subscription. N.B. When citing this work, cite the original published paper. Permanent link to this version: http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-188830 ACCEPTED MANUSCRIPT Modelling and numerical simulation of phase separation in polymer modified bitumen by phase-field method Jiqing Zhu a,*, Xiaohu Lu b, Romain Balieu a, Niki Kringos a a Department of Civil and Architectural Engineering, KTH Royal Institute of Technology, Brinellvägen 23, SE-100 44 Stockholm, Sweden b Nynas AB, SE-149 82 Nynäshamn, Sweden * Corresponding author. Email: [email protected] (J. Zhu) Abstract In this paper, a phase-field model with viscoelastic effects is developed for polymer modified bitumen (PMB) with the aim to describe and predict the PMB storage stability and phase separation behaviour. The viscoelastic effects due to dynamic asymmetry between bitumen and polymer are represented in the model by introducing a composition-dependent mobility coefficient. A double-well potential for PMB system is proposed on the basis of the Flory-Huggins free energy of mixing, with some simplifying assumptions made to take into account the complex chemical composition of bitumen. -
Utilization of Lactic Acid in Human Myotubes and Interplay with Glucose and Fatty Acid Metabolism Received: 12 January 2018 Jenny Lund1, Vigdis Aas2, Ragna H
www.nature.com/scientificreports OPEN Utilization of lactic acid in human myotubes and interplay with glucose and fatty acid metabolism Received: 12 January 2018 Jenny Lund1, Vigdis Aas2, Ragna H. Tingstad2, Alfons Van Hees2 & Nataša Nikolić1 Accepted: 11 June 2018 Once assumed only to be a waste product of anaerobe glycolytic activity, lactate is now recognized as Published: xx xx xxxx an energy source in skeletal muscles. While lactate metabolism has been extensively studied in vivo, underlying cellular processes are poorly described. This study aimed to examine lactate metabolism in cultured human myotubes and to investigate efects of lactate exposure on metabolism of oleic acid and glucose. Lactic acid, fatty acid and glucose metabolism were studied in myotubes using [14C(U)] lactic acid, [14C]oleic acid and [14C(U)]glucose, respectively. Myotubes expressed both the MCT1, MCT2, MCT3 and MCT4 lactate transporters, and lactic acid was found to be a substrate for both glycogen synthesis and lipid storage. Pyruvate and palmitic acid inhibited lactic acid oxidation, whilst glucose and α-cyano-4-hydroxycinnamic acid inhibited lactic acid uptake. Acute addition of lactic acid inhibited glucose and oleic acid oxidation, whereas oleic acid uptake was increased. Pretreatment with lactic acid for 24 h did not afect glucose or oleic acid metabolism. By replacing glucose with lactic acid during the whole culturing period, glucose uptake and oxidation were increased by 2.8-fold and 3-fold, respectively, and oleic acid oxidation was increased 1.4-fold. Thus, lactic acid has an important role in energy metabolism of human myotubes. Lactate is produced from glucose through glycolysis and the conversion of pyruvate by lactate dehydrogenase (LDH). -
Lactate Like Fluconazole Reduces Ergosterol Content in the Plasma Membrane and Synergistically Kills Candida Albicans
International Journal of Molecular Sciences Article Lactate Like Fluconazole Reduces Ergosterol Content in the Plasma Membrane and Synergistically Kills Candida albicans Jakub Suchodolski 1, Jakub Muraszko 1 , Przemysław Bernat 2 and Anna Krasowska 1,* 1 Department of Biotransformation, Faculty of Biotechnology, University of Wrocław, 50-383 Wrocław, Poland; [email protected] (J.S.); [email protected] (J.M.) 2 Department of Industrial Microbiology and Biotechnology, Faculty of Biology and Environmental Protection, University of Łód´z,90-237 Łód´z,Poland; [email protected] * Correspondence: [email protected] Abstract: Candida albicans is an opportunistic pathogen that induces vulvovaginal candidiasis (VVC), among other diseases. In the vaginal environment, the source of carbon for C. albicans can be either lactic acid or its dissociated form, lactate. It has been shown that lactate, similar to the popular antifungal drug fluconazole (FLC), reduces the expression of the ERG11 gene and hence the amount of ergosterol in the plasma membrane. The Cdr1 transporter that effluxes xenobiotics from C. albicans cells, including FLC, is delocalized from the plasma membrane to a vacuole under the influence of lactate. Despite the overexpression of the CDR1 gene and the increased activity of Cdr1p, C. albicans is fourfold more sensitive to FLC in the presence of lactate than when glucose is the source of carbon. We propose synergistic effects of lactate and FLC in that they block Cdr1 activity by delocalization due to changes in the ergosterol content of the plasma membrane. Citation: Suchodolski, J.; Muraszko, J.; Bernat, P.; Krasowska, A. Lactate Keywords: Candida albicans; lactate; fluconazole; ergosterol; Cdr1 Like Fluconazole Reduces Ergosterol Content in the Plasma Membrane and Synergistically Kills Candida albicans. -
Phase Diagrams and Phase Separation
Phase Diagrams and Phase Separation Books MF Ashby and DA Jones, Engineering Materials Vol 2, Pergamon P Haasen, Physical Metallurgy, G Strobl, The Physics of Polymers, Springer Introduction Mixing two (or more) components together can lead to new properties: Metal alloys e.g. steel, bronze, brass…. Polymers e.g. rubber toughened systems. Can either get complete mixing on the atomic/molecular level, or phase separation. Phase Diagrams allow us to map out what happens under different conditions (specifically of concentration and temperature). Free Energy of Mixing Entropy of Mixing nA atoms of A nB atoms of B AM Donald 1 Phase Diagrams Total atoms N = nA + nB Then Smix = k ln W N! = k ln nA!nb! This can be rewritten in terms of concentrations of the two types of atoms: nA/N = cA nB/N = cB and using Stirling's approximation Smix = -Nk (cAln cA + cBln cB) / kN mix S AB0.5 This is a parabolic curve. There is always a positive entropy gain on mixing (note the logarithms are negative) – so that entropic considerations alone will lead to a homogeneous mixture. The infinite slope at cA=0 and 1 means that it is very hard to remove final few impurities from a mixture. AM Donald 2 Phase Diagrams This is the situation if no molecular interactions to lead to enthalpic contribution to the free energy (this corresponds to the athermal or ideal mixing case). Enthalpic Contribution Assume a coordination number Z. Within a mean field approximation there are 2 nAA bonds of A-A type = 1/2 NcAZcA = 1/2 NZcA nBB bonds of B-B type = 1/2 NcBZcB = 1/2 NZ(1- 2 cA) and nAB bonds of A-B type = NZcA(1-cA) where the factor 1/2 comes in to avoid double counting and cB = (1-cA). -
Phase Separation Phenomena in Solutions of Polysulfone in Mixtures of a Solvent and a Nonsolvent: Relationship with Membrane Formation*
Phase separation phenomena in solutions of polysulfone in mixtures of a solvent and a nonsolvent: relationship with membrane formation* J. G. Wijmans, J. Kant, M. H. V. Mulder and C. A. Smolders Department of Chemical Technology, Twente University of Technology, PO Box 277, 7500 AE Enschede, The Netherlands (Received 22 October 1984) The phase separation phenomena in ternary solutions of polysulfone (PSI) in mixtures of a solvent and a nonsolvent (N,N-dimethylacetamide (DMAc) and water, in most cases) are investigated. The liquid-liquid demixing gap is determined and it is shown that its location in the ternary phase diagram is mainly determined by the PSf-nonsolvent interaction parameter. The critical point in the PSf/DMAc/water system lies at a high polymer concentration of about 8~o by weight. Calorimetric measurements with very concentrated PSf/DMAc/water solutions (prepared through liquid-liquid demixing, polymer concentration of the polymer-rich phase up to 60%) showed no heat effects in the temperature range of -20°C to 50°C. It is suggested that gelation in PSf systems is completely amorphous. The results are incorporated into a discussion of the formation of polysulfone membranes. (Keywords: polysulfone; solutions; liquid-liquid demixing; crystallization; membrane structures; membrane formation) INTRODUCTION THEORY The field of membrane filtration covers a broad range of Membrane formation different separation techniques such as: hyperfiltration, In the phase inversion process a membrane is made by reverse osmosis, ultrafiltration, microfiltration, gas sepa- casting a polymer solution on a support and then bringing ration and pervaporation. Each process makes use of the solution to phase separation by means of solvent specific membranes which must be suited for the desired outflow and/or nonsolvent inflow. -
United States Patent (10) Patent No.: US 8.450,378 B2 Snyder Et Al
USOO8450378B2 (12) United States Patent (10) Patent No.: US 8.450,378 B2 Snyder et al. (45) Date of Patent: *May 28, 2013 (54) ANTIVIRAL METHOD 5,944.912 A 8/1999 Jenkins ........................... 134/40 5,951,993 A 9, 1999 Scholz. ....... ... 424/405 (75) Inventors: Marcia Snyder, Stow, OH (US); David 6,022,5515,965,610 A 10/19992/2000 JampaniModak et ..... al. ... 424/405514,494 R. Macinga, Stow, OH (US); James W. 6,025,314. A 2/2000 Nitsch ... ... 510,221 Arbogast, Bath, OH (US) 6,034,133. A 3/2000 Hendley . 514,573 6,080,417 A 6/2000 Kramer ......................... 424/405 (73) Assignee: GOJO Industries, Inc., Akron, OH 6,090,395 A 7/2000 ASmuS (US) 6,107,261 A 8/2000 Taylor ........................... 510,131 6,110,908 A 8/2000 Guthery . 514,188 (*) Notice: Subject to any disclaimer, the term of this 8:35, A 858 Flying . patent is extended or adjusted under 35 6,183,766 B1 2/2001 Sine et al. ... 424/405 U.S.C. 154(b) by 716 days. 6,204.230 B1 3/2001 Taylor ........ ... 510,131 6,294, 186 B1 9/2001 Beerse et al. ... 424/405 This patent is Subject to a terminal dis- 6,319,958 B1 1 1/2001 Johnson ..... 514,739 claimer. 6,326,430 B1 12/2001 Berte ..... 524,555 6,352,701 B1 3/2002 Scholz. ... ... 424/405 (21) Appl. No.: 12/189,139 6,423,329 B1 7/2002 Sine et al. .. ... 424/405 6,436,885 B2 8/2002 Biedermann . ... 510,131 6,468,508 B1 10/2002 Laughlin .. -
Antifungal Effects of Lactobacillus Species Isolated from Local Dairy Products
[Downloaded free from http://www.jpionline.org on Sunday, September 17, 2017, IP: 78.39.35.67] Original Research Article Antifungal effects of Lactobacillus species isolated from local dairy products Sahar Karami, Mohammad Roayaei, Elnaz Zahedi, Mahmoud Bahmani1, Leila Mahmoodnia2, Hosna Hamzavi, Mahmoud Rafieian-Kopaei3 Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahwaz, 1Department of Pharmacology, Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Ilam, 3Department of Pharmacology, Medical Plants Research Center, Basic Health Sciences Institute, 2Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran Abstract Objective: The Lactobacillus is a genus of lactic acid bacteria which are regularly rod‑shaped, nonspore, Gram‑positive, heterogeneous, and are found in a wide range of inhabitants such as dairy products, plants, and gastrointestinal tract. A variety of antimicrobial compounds and molecules such as bacteriocin are produced by these useful bacteria to inhibit the growth of pathogenic microbes in the food products. This paper aims to examine the isolation of Lactobacillus from local dairies as well as to determine their inhibition effect against a number of pathogens, such as two fungi: Penicillium notatum and Aspergillus fulvous. Materials and Methods: Twelve Lactobacillus isolates from several local dairies. After initial dilution (10−1–10−3) and culture on the setting, de Man, Rogosa and Sharpe‑agar, the isolates were recognized and separated by phenotypic characteristics and biochemical; then their antifungal effect was examined by two methods. Results: Having separated eight Lactobacillus isolates, about 70% of the isolates have shown the inhabiting areas of antifungus on the agar‑based setting, but two species Lactobacillus alimentarius and Lactobacillus delbrueckii have indicated a significant antifungal effect against P. -
Partition Coefficients in Mixed Surfactant Systems
Partition coefficients in mixed surfactant systems Application of multicomponent surfactant solutions in separation processes Vom Promotionsausschuss der Technischen Universität Hamburg-Harburg zur Erlangung des akademischen Grades Doktor-Ingenieur genehmigte Dissertation von Tanja Mehling aus Lohr am Main 2013 Gutachter 1. Gutachterin: Prof. Dr.-Ing. Irina Smirnova 2. Gutachterin: Prof. Dr. Gabriele Sadowski Prüfungsausschussvorsitzender Prof. Dr. Raimund Horn Tag der mündlichen Prüfung 20. Dezember 2013 ISBN 978-3-86247-433-2 URN urn:nbn:de:gbv:830-tubdok-12592 Danksagung Diese Arbeit entstand im Rahmen meiner Tätigkeit als wissenschaftliche Mitarbeiterin am Institut für Thermische Verfahrenstechnik an der TU Hamburg-Harburg. Diese Zeit wird mir immer in guter Erinnerung bleiben. Deshalb möchte ich ganz besonders Frau Professor Dr. Irina Smirnova für die unermüdliche Unterstützung danken. Vielen Dank für das entgegengebrachte Vertrauen, die stets offene Tür, die gute Atmosphäre und die angenehme Zusammenarbeit in Erlangen und in Hamburg. Frau Professor Dr. Gabriele Sadowski danke ich für das Interesse an der Arbeit und die Begutachtung der Dissertation, Herrn Professor Horn für die freundliche Übernahme des Prüfungsvorsitzes. Weiterhin geht mein Dank an das Nestlé Research Center, Lausanne, im Besonderen an Herrn Dr. Ulrich Bobe für die ausgezeichnete Zusammenarbeit und der Bereitstellung von LPC. Den Studenten, die im Rahmen ihrer Abschlussarbeit einen wertvollen Beitrag zu dieser Arbeit geleistet haben, möchte ich herzlichst danken. Für den außergewöhnlichen Einsatz und die angenehme Zusammenarbeit bedanke ich mich besonders bei Linda Kloß, Annette Zewuhn, Dierk Claus, Pierre Bräuer, Heike Mushardt, Zaineb Doggaz und Vanya Omaynikova. Für die freundliche Arbeitsatmosphäre, erfrischenden Kaffeepausen und hilfreichen Gespräche am Institut danke ich meinen Kollegen Carlos, Carsten, Christian, Mohammad, Krishan, Pavel, Raman, René und Sucre. -
Chapter 9: Other Topics in Phase Equilibria
Chapter 9: Other Topics in Phase Equilibria This chapter deals with relations that derive in cases of equilibrium between combinations of two co-existing phases other than vapour and liquid, i.e., liquid-liquid, solid-liquid, and solid- vapour. Each of these phase equilibria may be employed to overcome difficulties encountered in purification processes that exploit the difference in the volatilities of the components of a mixture, i.e., by vapour-liquid equilibria. As with the case of vapour-liquid equilibria, the objective is to derive relations that connect the compositions of the two co-existing phases as functions of temperature and pressure. 9.1 Liquid-liquid Equilibria (LLE) 9.1.1 LLE Phase Diagrams Unlike gases which are miscible in all proportions at low pressures, liquid solutions (binary or higher order) often display partial immiscibility at least over certain range of temperature, and composition. If one attempts to form a solution within that certain composition range the system splits spontaneously into two liquid phases each comprising a solution of different composition. Thus, in such situations the equilibrium state of the system is two phases of a fixed composition corresponding to a temperature. The compositions of two such phases, however, change with temperature. This typical phase behavior of such binary liquid-liquid systems is depicted in fig. 9.1a. The closed curve represents the region where the system exists Fig. 9.1 Phase diagrams for a binary liquid system showing partial immiscibility in two phases, while outside it the state is a homogenous single liquid phase. Take for example, the point P (or Q). -
Malta Medicines List April 08
Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal -
Calcium Chloride
Iodine Livestock 1 2 Identification of Petitioned Substance 3 4 Chemical Names: 7553-56-2 (Iodine) 5 Iodine 11096-42-7 (Nonylphenoxypolyethoxyethanol– 6 iodine complex) 7 Other Name: 8 Iodophor Other Codes: 9 231-442-4 (EINECS, Iodine) 10 Trade Names: CAS Numbers: 11 FS-102 Sanitizer & Udderwash 12 Udder-San Sanitizer and Udderwash 13 14 Summary of Petitioned Use 15 The National Organic Program (NOP) final rule currently allows the use of iodine in organic livestock 16 production under 7 CFR §205.603(a)(14) as a disinfectant, sanitizer and medical treatment, as well as 7 CFR 17 §205.603(b)(3) for use as a topical treatment (i.e., teat cleanser for milk producing animals). In this report, 18 updated and targeted technical information is compiled to augment the 1994 Technical Advisory Panel 19 (TAP) Report on iodine in support of the National Organic Standard’s Board’s sunset review of iodine teat 20 dips in organic livestock production. 21 Characterization of Petitioned Substance 22 23 Composition of the Substance: 24 A variety of substances containing iodine are used for antisepsis and disinfection. The observed activity of 25 these commercial disinfectants is based on the antimicrobial properties of molecular iodine (I2), which 26 consists of two covalently bonded atoms of elemental iodine (I). For industrial uses, I2 is commonly mixed 27 with surface-active agents (surfactants) to enhance the water solubility of I2 and also to sequester the 28 available I2 for extended release in disinfectant products. Generally referred to as iodophors, these 29 “complexes” consist of up to 20% I2 by weight in loose combination with nonionic surfactants such as 30 nonylphenol polyethylene glycol ether (Lauterbach & Uber, 2011). -
Estonian Statistics on Medicines 2016 1/41
Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole